Le Lézard
Classified in: Health
Subject: v

Healthcare Special Opportunities Fund Announces March 2019 Quarterly Distribution


NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

TORONTO, March 22, 2019 (GLOBE NEWSWIRE) -- (TSX: MDS.UN) ? LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.0581 per Class A unit and US$0.0542 per Class U unit. The distribution will be paid on or before April 19, 2019 to unitholders of record on April 1, 2019. 

For further information please contact:

Michael B. Decter
President & Chief Executive Officer
LDIC Inc.
Tel: (416) 362-4141
Email: [email protected]
Website: www.ldic.ca


These press releases may also interest you

at 05:09
Sectra publishes Annual Report and Sustainability Report for 2023/2024
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
India-Based Dhiti Omics is Now Live on SOPHiA DDMtm
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI: Appointment of Adviser
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

More news about Health...


News published on and distributed by: